Literature DB >> 35797144

Complications of severe acute respiratory syndrome coronavirus 2 infection in children.

Roberta Caorsi1, Adele Civino2, Angelo Ravelli3,4.   

Abstract

PURPOSE OF REVIEW: Although during the initial stages of COVID-19 pandemic, the pediatric population seemed to be less affected, a number of SARS-CoV-2-related manifestations emerged over time, the principal of which is the multisystem inflammatory syndrome in children (MIS-C). Here we provide an update on the main pediatric disorders associated with SARS-CoV-2 infection. RECENT
FINDINGS: MIS-C is novel postinfectious manifestation with clinical features similar to Kawasaki disease and characterized by intense systemic inflammation affecting multiple organs. Many children required intensive care therapy because of circulatory shock, usually of myocardial origin. Appropriate treatment with immunomodulatory therapies led to favorable outcomes in most patients, with recovery of overall health and cardiac dysfunction. In addition to MIS-C, a variety of other complications of COVID-19 in children have been described, including thrombotic events, neurologic manifestations, and chilblain-like lesions. There is still uncertainty about the true prevalence of long COVID in children and its distinction from pandemic-related complaints.
SUMMARY: The experience gained so far with MIS-C and the other SARS-CoV-2-related complications in children and adolescents will facilitate accurate diagnosis and appropriate treatment. Further studies are needed to elucidate the pathophysiology of MIS-C and to determine the real impact of long-COVID in the pediatric age group.
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2022        PMID: 35797144     DOI: 10.1097/BOR.0000000000000892

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   4.941


  1 in total

1.  Editorial: COVID-19 and hyper inflammation syndrome: Different presentation and management.

Authors:  Dimitri Poddighe; Vahid Ziaee; Ozgur Kasapcopur
Journal:  Front Pediatr       Date:  2022-09-09       Impact factor: 3.569

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.